The Application dimension of the Third‑party Medical Testing Services market is organized around five primary use cases that collectively drive revenue. Diagnostic testing—including pathology, microbiology, and radiology support—accounts for roughly 45% of market volume, reflecting its central role in routine patient care and hospital outsourcing strategies. Clinical trial services represent about 20% of the market, as pharmaceutical sponsors increasingly rely on external labs for pharmacokinetic, biomarker, and safety analyses, thereby expanding the market taxonomy. Occupational health testing, comprising pre‑employment screenings, fitness‑for‑duty assessments, and exposure monitoring, contributes 15%, driven by regulatory compliance demands across manufacturing and construction sectors. Public‑health surveillance services, which include infectious‑disease monitoring and population‑level screening programs, hold a 10% share, supported by government contracts and pandemic‑response initiatives. Finally, wellness screening—preventive panels, biometric assessments, and lifestyle‑focused tests—also occupies 10%, fueled by corporate wellness programs and direct‑to‑consumer health trends. Together, these application segments delineate the market’s revenue composition and guide strategic investment decisions.